Shilpa Medicare gets CDSCO approval for hemostatic spray of Tranexamic Acid

20 Sep 2022 Evaluate

Shilpa Medicare has received CDSCO approval for its successful innovation of first in world topical hemostatic spray of Tranexamic Acid. This novel formulation of spray is simple, easy to carry, convenient to use and a lifesaving tool. Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic injury.

The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

321.85 0.65 (0.20%)
01-Jan-2026 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1714.40
Dr. Reddys Lab 1254.60
Cipla 1504.25
Zydus Lifesciences 910.05
Lupin 2084.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×